Skip to main content

silevertinib

Generic: Silevertinib·Code: BDTX-1535

silevertinib: sourced relationships with 1 company · 1 clinical trial tracked.

silevertinib evidence translation

What we can confirm

What it means

Source-backed records connect silevertinib to BDTX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could silevertinib → BDTX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Related indications

Epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) and glioblastoma (GBM); includes treatment of metastatic EGFR C797S mutation-positive NSCLC without T790M whose disease has progressed on/after a third-generation EGFR TKI; Phase 2 cohorts in 2L/3L EGFRm NSCLC with non-classical driver mutations and acquired C797S, and a 1L cohort in non-classical EGFR mutations; development for EGFR altered GBM being evaluated.Non-Small Cell Lung CancerGlioblastoma

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
Black Diamond Therapeutics, Inc. (BDTX)
developer · Reported 2024-03-12 · Current development: unknownSource
Epidermal growth factor receptor mutant (EGFRm) non-small ce…
Phase 2
Black Diamond Therapeutics, Inc. (BDTX)
developer · Reported 2026-03-16 · Current development: unknownSource
Non-Small Cell Lung Cancer
Phase 2
Clinical Trial Registry Records (1)

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK-triggered Expansion Cohort

NCT06072586Registry updated 2025-11-20·Early Phase 1
Recruiting

Primary endpoint: Unbound BDTX-1535 Concentration in Tumor Tissue

Interventionalopen82 targetStarted 2023-10Completion 2027-122 sites · United StatesSt. Joseph's Hospital and Medical Center, Phoenix

Frequently asked questions

Which companies have sourced relationships with silevertinib?

silevertinib has dated SEC/FDA relationship records for Black Diamond Therapeutics, Inc..

How many clinical trials involve silevertinib?

BioSniper tracks 1 clinical trial involving silevertinib.